Table 2.
Mixture no. | Ezetimibe recovery %a |
Atorvastatin calcium recovery %a |
|||||||
---|---|---|---|---|---|---|---|---|---|
Claimed taken (μg mL−1) |
IS |
||||||||
Atorvastatin | Ezetimibe | D1 | 224.6 nm | 238.6 nm | Reported methodb | D1 | D2 | Reported methodb | |
1 | 10 | 10 | 98.88 | 99.67 | 100.86 | 100.85 | 100.33 | 98.77 | 100.4 |
2 | 10 | 15 | 100.43 | 101.82 | 99.86 | 99.91 | 98.67 | 100.77 | 100.07 |
3 | 10 | 20 | 98.27 | 101.7 | 101.61 | 101.68 | 98.67 | 101.06 | 98.6 |
4 | 15 | 10 | 100.65 | 100.7 | 100.45 | 100.1 | 99.11 | 100.23 | 99.4 |
5 | 20 | 10 | 100.06 | 100.58 | 99.59 | 100.57 | 100.17 | 101.53 | 98.18 |
Mean ± S.D. | 99.66 ± 1.03 | 100.89 ± 0.89 | 100.47 ± 0.81 | 100.62 ± 0.70 | 99.39 ± 0.81 | 100.47 ± 1.06 | 99.33 ± 0.94 |
Average of three determinations.
Absorbance ratio method (Q-analysis) at 238.6 nm (iso-absorptive point) and 232.6 nm (λmax of Ezetimibe) [3].